
News|Videos|June 17, 2025
RX Review: RSV prevention and pediatric hospitalization
Fact checked by: Morgan Ebert, Executive Editor, Victoria Johnson
In this video, the first in a 3-part series, panelists discuss recent advancements in RSV management.
Advertisement
Advertisement
Respiratory syncytial virus (RSV) is a leading cause of hospitalization in infants and young children, placing a significant burden on families, hospitals, and the healthcare system. Recent advancements in RSV prevention, including maternal vaccination and long-acting monoclonal antibodies, are beginning to shift the clinical conversation from reactive management to proactive protection. In this HCP Live Network RX Review roundtable, moderator Albert Rizzo, MD, chief medical officer of the American Lung Association, leads a discussion on the evolving RSV landscape, with a focus on what these advances mean for pediatric care.
Related to this article

Diana F. Clarke, PharmD, explains how IMPAACT 2023 supported dolutegravir from birth, plus dosing tips and open questions for preterm infants.

An updated AAP policy statement renews the call to ban raw milk sales, citing pathogen risks to children and pregnant people and an emerging H5N1 concern.

At AAP 2026, Rana Hamdy, MD, discussed when to test children for group A strep, antibiotic selection, and strategies to improve prescribing.

Jonathan Miller, MD, discusses earlier HPV vaccination, individualized conversations with hesitant families, and strategies to improve vaccine uptake.

Jonathan Miller, MD, discusses factors behind lagging HPV vaccination rates and how pediatricians can address common parent concerns.

The latest IDSA histoplasmosis update adds a consensus statement on severe disease and outlines when children with pulmonary infection warrant itraconazole therapy.

Children with FASD given choline before age 6 had 9.1% higher nonverbal IQ and 11.3% better working memory vs placebo 5 years after treatment.
Advertisement
Advertisement

